{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:34:27Z","timestamp":1784900067136,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,10,3]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study assessed the long-term effects of triple therapy with prostanoids on patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as there is limited information on the safety and efficacy of this treatment approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted on patients with PAH-CHD who were actively followed up at our centre. All patients were already receiving dual combination therapy at maximum doses. Clinical characteristics, including functional class (FC), 6-minute walking test distance (6MWTD) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, were documented before initiating triple therapy and annually for a 2-year follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 60 patients were included in the study, with a median age of 41 years and 68% being women. Of these, 32 had Eisenmenger syndrome, 9 had coincidental shunts, 18 had postoperative PAH and 1 had a significant left-to-right shunt. After 1\u2009year of triple combination initiation, a significant improvement in 6MWTD was observed (406 vs 450; p=0.0027), which was maintained at the 2-year follow-up. FC improved in 79% of patients at 1\u2009year and remained stable in 76% at 2\u2009years. NT-proBNP levels decreased significantly by 2\u2009years, with an average reduction of 199\u2009ng\/L. Side effects were experienced by 33.3% of patients but were mostly mild and manageable. Subgroup analysis showed greater benefits in patients without Eisenmenger syndrome and those with pre-tricuspid defects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Triple therapy with prostanoids is safe and effective for patients with PAH-CHD, improving FC, 6MWTD and NT-proBNP levels over 2\u2009years. The treatment is particularly beneficial for patients with pre-tricuspid defects and non-Eisenmenger PAH-CHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2023-323015","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:21:10Z","timestamp":1698672070000},"page":"346-352","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-929X","authenticated-orcid":false,"given":"Raquel","family":"Luna-Lopez","sequence":"first","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0269-5574","authenticated-orcid":false,"given":"Teresa","family":"Segura de la Cal","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Sarnago Cebada","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"CIBERCV, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Martin de Miguel","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Williams","family":"Hinojosa","sequence":"additional","affiliation":[{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4037","authenticated-orcid":false,"given":"Alejandro","family":"Cruz-Utrilla","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Velazquez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"CIBERCV, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F","family":"Delgado","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"CIBERCV, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Arribas Ynsaurriaga","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"CIBERCV, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano-Sub\u00edas","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain"},{"name":"Pulmonary Hyertension Unit, Department of Cardiology. Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"CIBERCV, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2025092015130960000_110.5.346.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.04.072"},{"key":"2025092015130960000_110.5.346.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.037"},{"key":"2025092015130960000_110.5.346.3","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.ijcchd.2021.100144","article-title":"Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease","volume":"4","author":"van Dissel","year":"2021","journal-title":"International Journal of Cardiology Congenital Heart Disease"},{"key":"2025092015130960000_110.5.346.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01401-2019","article-title":"The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome","volume":"54","author":"D\u2019Alto","year":"2019","journal-title":"Eur Respir J"},{"key":"2025092015130960000_110.5.346.5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijcard.2019.07.004","article-title":"A single-centre, placebo-controlled, double-blind randomised cross-over study of Nebulised Iloprost in patients with Eisenmenger syndrome: A pilot study","volume":"299","author":"Nashat","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025092015130960000_110.5.346.6","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-305690"},{"key":"2025092015130960000_110.5.346.7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.21037\/cdt-21-351","article-title":"Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry","volume":"11","author":"Kaemmerer","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025092015130960000_110.5.346.8","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS)","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2025092015130960000_110.5.346.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa554"},{"key":"2025092015130960000_110.5.346.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2025092015130960000_110.5.346.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.503540"},{"key":"2025092015130960000_110.5.346.12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"2025092015130960000_110.5.346.13","doi-asserted-by":"crossref","first-page":"100353","DOI":"10.1016\/j.ijcchd.2022.100353","article-title":"Selexipag in patients with complex or uncorrected congenital heart disease: single centre experience","volume":"8","author":"Meras","year":"2022","journal-title":"International Journal of Cardiology Congenital Heart Disease"},{"key":"2025092015130960000_110.5.346.14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.21037\/cdt-22-266","article-title":"Long-term course of pulmonary arterial hypertension in adults with congenital heart disease under targeted therapy: a retrospective analysis of a single tertiary center","volume":"12","author":"Strack","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025092015130960000_110.5.346.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2025092015130960000_110.5.346.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2005.03.003"},{"key":"2025092015130960000_110.5.346.17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2018.10.012","article-title":"Real-life experience of inhaled Iloprost for patients with pulmonary arterial hypertension: insights from the Spanish REHAP Registry","volume":"275","author":"Del Pozo","year":"2019","journal-title":"Int J Cardiol"},{"key":"2025092015130960000_110.5.346.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2025092015130960000_110.5.346.19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025092015130960000_110.5.346.20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.2006.01685.x","article-title":"Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects","volume":"36 Suppl 3","author":"Sitbon","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"2025092015130960000_110.5.346.21","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307832"},{"key":"2025092015130960000_110.5.346.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.10.051"},{"key":"2025092015130960000_110.5.346.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.02.007"},{"key":"2025092015130960000_110.5.346.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.14.1858"},{"key":"2025092015130960000_110.5.346.25","doi-asserted-by":"crossref","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"2025092015130960000_110.5.346.26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension Registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur Respir J"},{"key":"2025092015130960000_110.5.346.27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ijcard.2015.02.031","article-title":"Pulmonary hypertension and congenital heart disease: an insight from the REHAP national Registry","volume":"184","author":"Alonso-Gonzalez","year":"2015","journal-title":"International Journal of Cardiology"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2023-323015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:13:19Z","timestamp":1758406399000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2023-323015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/heartjnl-2023-323015"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2023-323015","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}